The offering includes a 30-day over-allotment option to purchase an additional 495,000 shares worth $30.2 million, Plainsboro, N.J.-based Integra said.
The proceeds will be used to pay down debt, the company said.
J.P. Morgan, Wells Fargo Securities and RBC Capital Markets are slated to be book-runners for the offering, according to Integra.
Last week, Integra LifeSciences announced it beat expectations for its 2nd-quarter sales and earnings, but the medical device company still lowered its outlook for the rest of the year. SeaSpine Holdings (NSDQ:SPNE), Integra’s spine business spinout, didn’t fare as well with its Q2 preliminaries, missing expectations with its top-line prediction.